CLINICAL & PIPELINE·Drug Approval
Macleods Pharma's Generic Losartan/Hydrochlorothiazide Approval: A Decade of Market Impact and Regulatory Diligence
Macleods Pharmaceuticals Limited secured FDA approval for its generic Losartan Potassium and Hydrochlorothiazide (ANDA202289) on August 9, 2012. This significantly expanded access to an essential hypertension treatment, intensifying market competition and driving price adjustments. The subsequent decade of labeling updates underscores the continuous regulatory commitment required for generic pharmaceutical products, impacting procurement and regulatory strategies.
90-Day Activity